Dehydrated Amniotic Membrane Allograft for Treatment of Chronic Leg Ulcers in Patients With Multiple Comorbidities: A Case Series

The journal of the American College of Clinical Wound Specialists Pub Date : 2014-12-01 DOI:10.1016/j.jccw.2016.01.002

Stephen M. Barr MD, FAPWCA

{"title":"Dehydrated Amniotic Membrane Allograft for Treatment of Chronic Leg Ulcers in Patients With Multiple Comorbidities: A Case Series","authors":"Stephen M. Barr MD, FAPWCA","doi":"10.1016/j.jccw.2016.01.002","DOIUrl":null,"url":null,"abstract":"<div>Cellular and/or tissue-based products (CTPs) are emerging treatment options for chronic non-healing wounds. Dehydrated amniotic membrane allograft (DAMA) was used in 7 patients whose wounds had not responded adequately to standard and adjuvant therapies; four VLUs, 2 surgical wounds, and 1 DFU. Patients had multiple comorbidities, including 2 with autoimmune disorders (CREST syndrome and systemic lupus erythematosus). Patients received 3–8 applications of DAMA at weekly to biweekly intervals (average, 5.4 applications). Complete wound healing was observed in 6 of 7 patients during study period, with an average time to closure of 7.9 weeks. Closure was achieved in 3 of 7 patients after 3 DAMA applications. In the patient with CREST syndrome who did not completely close, DAMA reduced the area and volume by nearly 50% and later went on to closure. These cases suggest that DAMA is a viable option for recalcitrant DFUs, VLUs, and surgical wounds.</div>","PeriodicalId":90358,"journal":{"name":"The journal of the American College of Clinical Wound Specialists","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jccw.2016.01.002","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of the American College of Clinical Wound Specialists","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213510316000038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 7

Abstract

Cellular and/or tissue-based products (CTPs) are emerging treatment options for chronic non-healing wounds. Dehydrated amniotic membrane allograft (DAMA) was used in 7 patients whose wounds had not responded adequately to standard and adjuvant therapies; four VLUs, 2 surgical wounds, and 1 DFU. Patients had multiple comorbidities, including 2 with autoimmune disorders (CREST syndrome and systemic lupus erythematosus). Patients received 3–8 applications of DAMA at weekly to biweekly intervals (average, 5.4 applications). Complete wound healing was observed in 6 of 7 patients during study period, with an average time to closure of 7.9 weeks. Closure was achieved in 3 of 7 patients after 3 DAMA applications. In the patient with CREST syndrome who did not completely close, DAMA reduced the area and volume by nearly 50% and later went on to closure. These cases suggest that DAMA is a viable option for recalcitrant DFUs, VLUs, and surgical wounds.

Abstract Image

查看原文本刊更多论文

脱水羊膜异体移植治疗多重合并症患者的慢性腿部溃疡:一个病例系列

基于细胞和/或组织的产品(ctp)是慢性不愈合伤口的新兴治疗选择。采用脱水羊膜异体移植(DAMA)治疗7例标准及辅助治疗效果不佳的患者;4个vlu, 2个手术伤口，1个DFU。患者有多种合并症，包括2例自身免疫性疾病(CREST综合征和系统性红斑狼疮)。患者每隔一周至两周接受3-8次DAMA治疗(平均5.4次)。在研究期间，7例患者中有6例伤口完全愈合，平均愈合时间为7.9周。在3次DAMA应用后，7例患者中有3例实现闭合。在CREST综合征未完全闭合的患者中，DAMA使面积和体积减少了近50%，随后继续闭合。这些病例提示DAMA是治疗顽固性dfu、vlu和外科伤口的可行选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The journal of the American College of Clinical Wound Specialists

自引率

0.00%

发文量